Transaction DateRecipientSharesTypePriceValue
5th September 2019John Rodney Varner1,800Open or private purchase$0.89$1,594.62
Genprex logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Genprex, Inc. is a clinical stage gene therapy company. It develops the Oncoprex immunogene therapy which targets the non-small cell lung cancer and other solid tumors.

Ticker: GNPX
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1595248
Employees: 8
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags